Associated Papers
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
37483495 (PubMed )
Supplement: Table_6.xlsx › Comprehensive_panel
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K et al.
Molecular Oncology, 2021
33131198 (PubMed )
Supplement: MOL2-15-126-s007.xlsx › Table_S3
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
Clark TA et al.
The Journal of Molecular Diagnostics : Jmd, 2018
29936259 (PubMed )
Supplement: mmc12.xlsx › Table_S12
Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR et al.
Pathology Oncology Research : Por, 2015
Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.
Yunxia Z et al.
Bmc Medical Genetics, 2010
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib.
Zhang X et al.
Oncology Reports, 2008
The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers.
Mimori K et al.
Journal of Surgical Oncology, 2006
Somatic mutations of epidermal growth factor receptor in colorectal carcinoma.
Nagahara H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Select a paper to view details